The 2012 revised Dutch national guidelines for the treatment of chronic hepatitis B virus infection

Netherlands Journal of Medicine

Volumn 70, Issue 8, 2012, Pages 381-385

  Buster, E H C J ^a,b   Baak, B C ^c   Bakker, C M ^c   Beuers, U H W ^d   Brouwer, J T ^c   Drenth, J P H ^e   van Erpecum, K J ^f   van Hoek, B ^g   Honkoop, P ^a   Kerbert Dreteler, M J ^h   Koek, G H ⁱ   van Nieuwkerk, K M J ^j   van Soest, H ^k   van der Spek, B W ^b,l   Tan, A C I T L ^m   Vrolijk, J M ⁿ   Janssen, H L A ^b  

^a ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^h MEDISCH SPECTRUM TWENTE   (Netherlands)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^j VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^k MEDICAL CENTER HAAGLANDEN   (Netherlands)

^l Location Alkmaar   (Netherlands)

^m CANISIUS WILHELMINA HOSPITAL   (Netherlands)

ⁿ RIJNSTATE HOSPITAL   (Netherlands)

more..

Author keywords

Antiviral therapy; Guidelines; Hepatitis B virus; Pregnancy

Indexed keywords

ADEFOVIR; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; ENTECAVIR; GUANINE; LAMIVUDINE; NUCLEOSIDE; PHOSPHONIC ACID DERIVATIVE; TELBIVUDINE; TENOFOVIR; THYMIDINE;

ANTIVIRAL RESISTANCE; ARTICLE; BREAST MILK; DRUG APPROVAL; DRUG EFFECT; FEMALE; HEPATITIS B; HUMAN; KIDNEY FAILURE; NETHERLANDS; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; STANDARD; VERTICAL TRANSMISSION;

ADENINE; ANTIVIRAL AGENTS; DRUG APPROVAL; DRUG RESISTANCE, VIRAL; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MILK, HUMAN; NETHERLANDS; NUCLEOSIDES; ORGANOPHOSPHONATES; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RENAL INSUFFICIENCY; THYMIDINE;

EID: 84881297257     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486-95.
2. Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2008;48:750-8.
3. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2010;140:132-43.
4. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442-55.
5. Heathcote EJ, Marcellin P, Buti M, et al. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B. Gastroenterology. 2010:DOI 10.1053/j.gastro.2010.10.011.
6. Heathcote EJ, Gane E, De Man RA, et al. Long term (4 year) efficacy and safety of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (study 103): preliminary analysis. Hepatology. 2010;52:556A.
7. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73-80.
8. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25:387-94.
9. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. Aids. 2009;23:689-96.
10. Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422-30.
11. Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459-67.
12. Liaw YF, Xie Q, Han KB, et al. Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 1g: NEPTUNE study. Hepatology. 2010;52:429A-430A.
13. Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002-9.
14. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454-61.
15. Rijckborst V, Hansen BE, Ferenci P, et al. Early on-treatment HBsAg and HBV DNA levels identify HBeAg-negative patients not responding to 48 or 96 week of peginterferon alfa-2a therapy. Hepatology. 2010;52:552A-553A.
16. Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52:1251-7.
17. Jung YK, Yeon JE, Choi JH, et al. Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient. Gut Liver. 2010;4:389-93.
18. Verhelst D, Monge M, Meynard JL, et al Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis. 2002;40:1331-3.
19. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009;50:2001-6.
20. Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132-43.
21. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t) ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology. 2009;139:491-8.
22. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445-51.
23. Reijnders JG, Deterding K, Petersen J, et al. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol. 2009;52:493-500.
24. Reijnders JG, Pas SD, Schutten M, de Man RA, Janssen HL. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol. 2009;50:674-83.
25. Xu WM, Cui YT, Wang L, Yang H, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009;16:94-103.
26. Bzowej NH. Hepatitis B Therapy in Pregnancy. Curr Hepat Rep. 2010;9:197-204.
27. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat. 2008;15:37-41.
28. Lutgens SP, Nelissen EC, van Loo IH, Koek GH, Derhaag JG, Dunselman GA. To do or not to do: IVF and ICSI in chronic hepatitis B virus carriers. Hum Reprod. 2009;24:2676-8.